You’ve finished drafting the patent application for a critical, clinical stage invention. The scientific team wrote up the examples and they even included comparative data. You’ve finalized the claims and specification. You’re certain that the invention is novel. You’ve got your strategies for overcoming any potential inherent obviousness rejections nailed down. But have you given much thought to the enablement and written description requirements? Well you better, since Post-Grant Reviews are being instituted on the basis of 35 U.S.C. 112.
